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Acute transaminitis after initialdays of starting haloperidol
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Abstract
Haloperidol is a first-generation
antipsychotic butyrophenone that is
lipophilic, readily absorbed, and
extensively metabolized in the liver. The
occurrence of elevated liver enzymes with
haloperidol is reported to be 2.4% with
cases generally occurring in the setting of
chronic use. In this case, we present a
patient who developed elevated liver
enzymes 1-2 days after starting haloperidol
treatment on two separate occasions and in
the context of negative hepatic viral and
autoimmune serology. Liver enzymes
consistently had alanine transaminase >
aspartate transaminase and peaked at 288
U/L prior to discontinuation of the
medication. The patient was taken off
haloperidol after serology resulted and
clozapine regimen started. He was able to
tolerate clozapine well with recovery of his
transaminitis and psychiatric stabilization.
Introduction 
Haloperidol is a first-generation
antipsychotic butyrophenone that is
lipophilic and readily absorbed with
extensive metabolism occurring in the liver
and less than 1% of original drug excreted
in urine.1 In the liver, haloperidol is 50-60%
metabolized by glucuronidation and
approximately 25% percent by reduction.
The remaining 15-30% are through
oxidation reactions.2 CYP3A4 has been
considered as the major enzyme involved in
haloperidol reduction but CYP2D6 has also
shown influence in metabolism.3.4 Liver
toxicity from haloperidol has been well
studied in the chronic setting but few
reports show acute effects on the liver.5 In
this paper, we discuss an episode of
transaminitis concordant with starting and
restarting haloperidol in the context of
negative serology of liver pathology.
Case Report
A 44-year old man of Southeast Asian
origin with a past medical history of
substance use disorder (IV
methamphetamine and heroin) and
schizophrenia presented to the emergency
department after being found increasingly
disoriented while at a clinic visit. Prior
treatment of schizophrenia consisted of
paliperidone palmitate 234 mg every 28
days, his last dose was one week from his
presentation. While at the psychiatric center
at the University of California, Irvine (UCI)
the patient continued to have auditory
hallucinations (AH), visual hallucinations
(VH) and disorganized thinking.
Hallucinations included individuals
attempting to bite him if he did not put
toothpaste across his forehead. The patient
was initially started on thiamine and
risperidone but after no improvement in
symptoms a regimen of haloperidol was
started to supplement his long acting
injectable. A dose of 10 mg QHS was
initiated on 8/31 and then continued until
9/3 when the dose was increased to 15mg
QHS from 9/4 to 9/9. While on treatment, a
CMP revealed that the patient had
developed a transaminitis that showed an
elevated Alkaline Phosphatase, and an
Alanine Transaminase (ALT) greater than
Aspartate Transaminase (AST). The ALT
was three times normal at 166U/L on 9/7
from his baseline of 51 taken at 8/27 (Figure
1). A thorough history and physical revealed
that the patient had no symptoms of
abdominal pain, no icterus, jaundice,
hepatomegaly on percussion, or abdominal
tenderness. As a precaution, the patient was
discontinued from haloperidol on 9/9 and
showed improvement in ALT levels down
to 100 U/L two days after (Figure 1). The
patient was started on a clozapine taper of
25 mg daily increments with the first 25mg
dose given on 9/10. Despite having
improvement in liver function testing, it
was still uncertain if the transaminitis was
drug-induced or due to underlying liver
pathology given patient’s history of IV
substance abuse. Hepatology was consulted
at the time, and a full serologic workup of
liver pathology was ordered: Hepatitis A,B,
and C; Anti-Smooth Muscle Ab, Anti-
Mitochondrial Ab, Anti-Nuclear Ab. While
labs were pending, the patient began to have
worsening hallucinations and aggression, so
haloperidol was restarted on 9/12 to 9/14 as
a 10mg QHS dose that was tapered to 5mg
QHS on 9/15 and 9/16 (Figure 2). Once
again, the AST and ALT levels rose with
ALT being higher, reaching a peak of 288
U/L on 9/18. The patient was monitored for
several days after stopping haloperidol on
9/16 with a continued clozapine regimen of
200mg QHS. On 9/27 the patient continued
to recover from his transaminitis and had an
ALT level of 71. The patient was stabilized
on clozapine for psychiatric management
and tolerated the new regimen well.
Discussion
In the patient described above, a notable
transaminitis was found on routine labs that
was temporally correlated with starting
haloperidol while in the psychiatric ward.
The patient was tested for serologies for
Hepatitis A, B, and C, negative autoimmune
hepatitis including Anti-Mitochondrial Ab,
Anti-Nuclear Ab, Anti-Smooth Muscle Ab.
After stopping the medication and
beginning clozapine therapy, the
transaminitis correspondingly began to
resolve consistent with the hypothesis of an
acute drug toxicity secondary to starting
haloperidol. Due to extenuating
circumstance of the patient’s worsening
psychosis, recovering transaminitis, and
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pending hepatologic serologies, haloperidol
was restarted while clozapine was gradually
increased. Subsequently, the patient once
again developed a transaminitis and showed
recovery after immediately stopping the
medication, thereby strengthening evidence
for haloperidol toxicity. It is interesting to
note that the patient developed a
transaminitis more severe when given the
second trial. This secondary increased
elevation in Liver Function Test (LFT)
levels also may suggest a sensitivity
reaction with worsening effects with each
treatment dose (Figure 3). A report has also
shown evidence for hypersensitivity
reactions with elevated eosinophils.6 This
patient did not have any significant or
abnormal elevation in eosinophils.
The incidence of haloperidol induced
hepatitis is studied to be approximately
2.4%7, however the incidence of acute
transaminitis immediately following drug
therapy has not been well studied. This is
not the first case of an acute haloperidol-
induced transaminitis, Ouanes et al. had a
similar report showing an eight-fold
increase in transaminases (with ALT>AST)
10 days after initiating treatment with
haloperidol.8 This case study adds further
support with of an acute haloperidol
transaminitis with worsening hepatitis with
subsequent trials. The temporal association
between initiating haloperidol treatment
and the transaminitis, in the context of
negative serologies and a controlled
environment, yields strong evidence for the
consideration of haloperidol as a culpable
agent in elevated liver enzymes.
Conclusions
Acute haloperidol-induced
transaminitis is not well studied, with only
one case report presuming the drug was the
culprit due to the context of negative
serology and liver scan.8 In this case, we
provided temporal relation to starting and
stopping haloperidol with the rise and fall
of liver enzymes. The patient was
asymptomatic throughout the time course,
had negative hepatic serologies, and was
able to fully recover. The patient was
closely monitored for transaminitis despite
the scant evidence of an acute haloperidol
transaminitis and thus was taken off the
medication as much as possible without
being detrimental to his psychiatric
wellbeing. He tolerated the change to a
clozapine well and stabilized
psychiatrically and medically on the new
regimen. 
                             Case Report
Figure 1. Graphical representation of ALT, AST, and Alkaline Phosphatase (Alk Phos)
before and after initially starting haloperidol treatment. The shaded area shows days
where patient was taking either 10 mg haloperidol or 15 mg haloperidol.
Figure 2. Graphical representation of ALT, AST, and Alkaline Phosphatase before and
after second attempt of haloperidol treatment. The shaded area shows days of haloperidol
treatment of 10 mg or 5 mg.
Figure 3. Graphical representation of ALT, AST, and Alkaline Phosphatase throughout
treatment course. The shaded area shows days of haloperidol treatment of 10 mg, 15 mg,
10 mg, and 5 mg respectively from left to right.
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